AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie genentech Collaboration (Venclexta) — Profit Share & Royalties in Cost of Products Sold ($M) ($M)
Form 10-Q / 10-K Licensing, Acquisitions & Other Arrangements Note
Latest, FY2025
1,064
Period ended Dec 31, 2025
Change on a year earlier
+7.5%
990 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Genentech Collaboration (Venclexta) — Profit Share & Royalties in Cost of Products Sold ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,064 | +7.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 990 | +13.9% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 869 | +11.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 778 | +10.7% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 703 | +31.9% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 533 | +66.6% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 320 | +127.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 141 | – | Form 10-K (filed 2021-02-19) ↗ |
Breakdown
What makes up genentech collaboration (venclexta) — profit share & royalties in cost of products sold ($m)
Cite this data
StockData. (2026). AbbVie Genentech Collaboration (Venclexta) — Profit Share & Royalties in Cost of Products Sold ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/collab_genentech_cogs
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.